InspireMD (NSPR) analyst forecast and price target
Analyst forecast
Consensus of 3 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Piper Sandler | Maintained | Overweight | $3.00 from $4.00 | May 5, 2026 |
| Piper Sandler | Maintained | Overweight | $4.00 from $4.50 | May 12, 2025 |
| Lake Street | Initiated Coverage | Buy | $5.00 | Dec 11, 2024 |
| Piper Sandler | Maintained | Overweight | $4.50 | Sep 17, 2024 |
| Piper Sandler | Maintained | Overweight | $4.50 from $3.50 | Nov 2, 2023 |
| National Alliance Securities | Maintained | Buy | $4.75 from $5.15 | May 17, 2023 |
Frequently asked questions
Is NSPR a buy, sell, or hold?
Analysts covering InspireMD currently average a Buy rating: 3 buy, 0 hold and 0 sell, from 3 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on NSPR?
On May 5, 2026, Piper Sandler maintained InspireMD at Overweight with a price target of $3.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.